{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T22:44:31Z","timestamp":1648853071568},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,1,16]],"date-time":"2010-01-16T00:00:00Z","timestamp":1263600000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s00292-009-1261-x","type":"journal-article","created":{"date-parts":[[2010,1,14]],"date-time":"2010-01-14T04:18:19Z","timestamp":1263442699000},"page":"29-41","source":"Crossref","is-referenced-by-count":1,"title":["Chronische myeloische Neoplasien"],"prefix":"10.1007","volume":"31","author":[{"given":"A.H.","family":"Schmitt-Graeff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,16]]},"reference":[{"key":"1261_CR1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasm and acute leukemia: rationale and important changes. Blood 114:937\u2013951","journal-title":"Blood"},{"key":"1261_CR2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14\u201322","journal-title":"Leukemia"},{"key":"1261_CR3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ajh.21183","volume":"83","author":"Tefferi","year":"2008","unstructured":"Tefferi A (2008) Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 83:491\u2013497","journal-title":"Am J Hematol"},{"key":"1261_CR4","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","volume":"112","author":"Levine","year":"2008","unstructured":"Levine RL, Gilliland DG (2008) Myeloproliferative disorders. ASH 50th anniversary review. Blood 112:2190\u20132197","journal-title":"Blood"},{"key":"1261_CR5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3324\/haematol.10328","volume":"92","author":"Reiter","year":"2007","unstructured":"Reiter A, Grimwade D, Cross NCP (2007) Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. Haematologica 92:1153\u20131158","journal-title":"Haematologica"},{"key":"1261_CR6","unstructured":"Vardiman JW, Melo JV, Baccarani M, Thiele J (2008) Chronic myelogeneous leukaemia, BCR-ABL1 positive. In: Swerdlow S, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon, pp\u00a032\u201337"},{"key":"1261_CR7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/10428190009148850","volume":"36","author":"Thiele","year":"2000","unstructured":"Thiele J, Kvasnicka HM, Schmitt-Graeff A et al (2000) Bone marrow features and clinical findings in chronic myeloid leukaemia \u2013 a comparative, multicenter, immunohistological and morphometric study on 614 patients. Leuk Lymphoma 36:295\u2013308","journal-title":"Leuk Lymphoma"},{"key":"1261_CR8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(07)70294-2","volume":"8","author":"B\u00fcsche","year":"2007","unstructured":"B\u00fcsche G, Hussein K, Bock O, Kreipe H (2007) Insights into JAK2-V617F mutation in CML. Lancet Oncol 8:863\u2013864","journal-title":"Lancet Oncol"},{"key":"1261_CR9","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.leu.2404993","volume":"22","author":"Hussein","year":"2008","unstructured":"Hussein K, Bock O, Theophile K et al (2008) Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 22:1059\u20131062","journal-title":"Leukemia"},{"key":"1261_CR10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.V99.1.381","volume":"99","author":"Beham-Schmid","year":"2002","unstructured":"Beham-Schmid C, Apfelbeck U, Sill H et al (2002) Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99:381\u2013383","journal-title":"Blood"},{"key":"1261_CR11","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1182\/blood-2003-08-2734","volume":"103","author":"Kvasnicka","year":"2004","unstructured":"Kvasnicka HM, Thiele J, Staib P et al (2004) Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 103:3549\u20133551","journal-title":"Blood"},{"key":"1261_CR12","doi-asserted-by":"crossref","unstructured":"Schmitt-Graeff A, Hochhaus A (2006) Hematological side effects of tyrosine kinase inhibition using imatinib. (H\u00e4matologische Nebenwirkungen der Tyrosinkinase-Inhibition mit Imatinib.) Pathologe 27:40\u201346","DOI":"10.1007\/s00292-005-0806-x"},{"key":"1261_CR13","unstructured":"Thiele J, Kvasnicka HM, Orazi A et al (2008) Polycythemia vera. In: Swerdlow S, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon, pp\u00a040\u201343"},{"key":"1261_CR14","unstructured":"Thiele J, Kvasnicka HM, Orazi A et al (2008) Essential thrombocythemia. In: Swerdlow S, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon. pp\u00a048\u201350"},{"key":"1261_CR15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","volume":"111","author":"Wilkens","year":"2008","unstructured":"Wilkens BS, Erber WN, Bareford D et al (2008) Bone marrow pathology in essential thrombocythemia. Interobserver reliability and utility for dentifying disease subtypes. Blood 111:60\u201370","journal-title":"Blood"},{"key":"1261_CR16","first-page":"1128","volume":"90","author":"Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F et al (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128\u20131132","journal-title":"Haematologica"},{"key":"1261_CR17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2353\/ajpath.2008.071030","volume":"172","author":"Bock","year":"2008","unstructured":"Bock O, H\u00f6ftmann J, Theophile K et al (2008) Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. Am J Pathol 172:951\u2013960","journal-title":"Am J Pathol"},{"key":"1261_CR18","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.exphem.2007.08.022","volume":"35","author":"Kr\u00f6ger","year":"2007","unstructured":"Kr\u00f6ger N, Thiele J, Zander A et al (2007) Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 35:1719\u20131722","journal-title":"Exp Hematol"},{"key":"1261_CR19","unstructured":"Bain BJ, Brunning RD, Vardiman JW, Thiele J (2008a) Chronic neutrophilic leukaemia. In: Swerdlow S, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon, pp\u00a038\u201339"},{"key":"1261_CR20","unstructured":"Bain BJ, Gilliland DG, Vardiman JW, Horny HP (2008b) Chronic eosinophilic leukaemia, not otherwise specified. In: Swerdlow S, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon, pp\u00a051\u201353"},{"key":"1261_CR21","unstructured":"Kvasnicka HM, Bain BJ, Thiele J et al (2008) Myeloproliferative neoplasm, unclassifiable. In: Swerdlow S, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon, pp\u00a064\u201365"},{"key":"1261_CR22","unstructured":"Horny HP, Metcalfe DD, Bennett JM et al (2008) Mastocytosis. In: Swerdlow S, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon, pp\u00a054\u201363"},{"key":"1261_CR23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3324\/haematol.12324","volume":"93","author":"Tefferi","year":"2008","unstructured":"Tefferi A, Verstovsek S, Pardanani A (2008) How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica 93:6\u20139","journal-title":"Haematologica"},{"key":"1261_CR24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2353\/jmoldx.2008.070061","volume":"10","author":"Sotlar","year":"2008","unstructured":"Sotlar K, Bache A, Stellmacher F et al (2008) Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816\u00a0V and JAK2V617F. J Mol Diagn 10:58\u201366","journal-title":"J Mol Diagn"},{"key":"1261_CR25","unstructured":"Bain BJ, Gilliland DG, Horny HP, Vardiman JW (2008c) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow S, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon, pp\u00a068\u201373"},{"key":"1261_CR26","unstructured":"Orazi A, Bennett JM, Germing U et al (2008) Chronic myelomonocytic leukaemia. In: Swerdlow S, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon, pp\u00a076\u201379"},{"key":"1261_CR27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3324\/haematol.11581","volume":"93","author":"Schmitt-Graeff","year":"2008","unstructured":"Schmitt-Graeff AH, Teo SS, Olschewski M et al (2008) The JAK2-V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 93:34\u201340","journal-title":"Haematologica"},{"key":"1261_CR28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","volume":"143","author":"Metzgeroth","year":"2008","unstructured":"Metzgeroth G, Walz C, Erben P et al (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 143:707\u2013715","journal-title":"Br J Haematol"},{"key":"1261_CR29","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","volume":"108","author":"Kiladjian","year":"2006","unstructured":"Kiladjian JJ, Cassinat B, Turlure P et al (2006) High molecular response rate of polycythemia patients treated with pegylated interferon alpha-2a. Blood 108:2037\u20132040","journal-title":"Blood"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-009-1261-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-009-1261-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-009-1261-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T07:01:04Z","timestamp":1559026864000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-009-1261-x"}},"subtitle":["Diagnostische Kriterien und Ausblick auf aktuelle Theapiekonzepte"],"short-title":[],"issued":{"date-parts":[[2010,1,16]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1007\/s00292-009-1261-x","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,16]]}}}